Company intelligence / Profile preview
Percheron Therapeutics
Melbourne, Victoria, Australiapercherontx.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
ATL1102, an antisense oligonucleotide targeting VLA4, is in an international Phase IIb trial for Duchenne muscular dystrophy and has shown positive efficacy signals in a prior Phase IIa study. It also has potential efficacy in multiple sclerosis and other indications. ATL1103 (atesidorsen), targeting the growth hormone receptor for acromegaly, has completed Phase II trials with significant reduction of IGF-I levels.
- Therapeutic areas
- PulmonologyRare DiseasesNeurologyEndocrinology
- Modalities
- Antisense oligonucleotide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Ionis Pharmaceuticals Inc. – licensing partner for antisense technology
Beyond the preview
Go deeper on Percheron Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Percheron Therapeutics.